J&J nabs FDA okay for BCMA bispecific Tecvayli

J&J nabs FDA okay for BCMA bispecific Tecvayli

Source: 
Pharmaphorum
snippet: 

Johnson & Johnson has secured another regulatory approval for its BCMAxCD3 bispecific antibody for multiple myeloma – Tecvayli – adding to the wide range of therapies available for the blood cancer.